The UDP-glucuronosyltransferase (UGT) 1A9 has been shown to play an important role in the detoxification of several carcinogens and clearance of anticancer and pain medications. The goal of the present study was to identify novel polymorphisms in UGT1A9 and characterize their effect on glucuronidation activity. The UGT1A9 gene was analyzed by direct sequencing of buccal cell genomic DNA from 90 healthy subjects. In addition to a previously identified single nucleotide polymorphism (SNP) at codon 33 resulting in an amino acid substitution (Met>Thr), two low-prevalence (<0.02) novel missense SNPs at codons 167 (Val>Ala) and 183 (Cys>Gly) were identified and are present in both white and African-American subjects. Glucuronidation activity assays using HEK293 
The UDP-glucuronosyltransferase (UGT) superfamily of enzymes catalyzes the glucuronidation of a variety of endogenous compounds such as bilirubin and steroid hormones, as well as xenobiotics such as drugs and environmental carcinogens (Tephly and Burchell, 1990; Owens and Ritter, 1995; Guéraud and Paris, 1998; Ren et al., 2000; Tukey and Strassburg, 2000) . The UGTs are membrane-bound proteins that, with the exception of UGT1A10 , reside mainly in the endoplasmic reticulum (Tukey and Strassburg, 2000) and are known to exist as monomeric proteins but are capable of homo-and heterodimerization (Ghosh et al., 2001; Operaña and Tukey, 2007) . The cysteine residues of UGT1A enzymes are highly conserved in all human family members ( Fig. 1 ) as well as in other mammals (Ghosh et al., 2005) , but the cysteine residues involved in dimerization and the functional implications of human UGT dimerization have yet to be elucidated.
Based on structural and amino acid sequence homology, UGTs are classified into several families and subfamilies (Mackenzie et al., 2005) . The two major families of the UGTs are the UGT1A and UGT2B families (Mackenzie et al., 2005) . Whereas the UGT2B family members are derived from independent genes located in chromosome 4, the entire UGT1A family is derived from a single gene locus in chromosome 2, coding for nine functional proteins that differ only in their amino terminus as a result of alternate splicing of independent exon 1 regions to a shared carboxyl terminus encoded by exons 2 to 5 (Owens and Ritter, 1995; Nagar and Remmel, 2006) . These independent exon 1 regions are responsible for the wide range of substrate specificity demonstrated by the UGT1A family of enzymes, whereas the common region coded by exons 2 to 5 is involved in UDP-glucuronic acid (UDPGA) binding ( Fig.  1 ) (Tukey and Strassburg, 2000) . Polymorphisms have been identified previously for many of the UGT genes and several recent studies have examined their potential role in carcinogenesis and in risk for several cancer types (Burchell and Hume, 1999; Zheng et al., 2001; Ockenga et al., 2003; Araki et al., 2005) . UGT1A9 has been shown to be one of the most active hepatic UGTs against a variety of substrates including several metabolites of the procarcinogen benzo [a] pyrene (B[a]P) (Dellinger et al., 2006) and is highly active against SN-38, the major active metabolite of the chemotherapeutic agent irinotecan (Gagné et al., 2002) . Furthermore, a single nucleotide polymorphism (SNP) identified in UGT1A9, resulting in a methionine to threonine amino acid substitution at codon 33 (UGT1A9 33Thr ), demonstrated decreased glucuronidation activity against SN-38 in vitro (Villeneuve et al., 2003) . This observation suggests that a genetic variation in the UGT1A9 enzyme may alter a patient's ability to metabolize irinotecan and could affect therapeutic efficacy and drug resistance. However, the effect of this SNP on the ability of UGT1A9 to glucuronidate carcinogens has not been addressed and could be important in identifying individuals at greater risk for cancer.
In the present study, the goal was to identify novel missense SNPs in the UGT1A9 gene and examine how they could potentially affect UGT1A9 function. In addition to the previously identified UGT1A9 33Thr polymorphism, two low-prevalence missense SNPs were also identified in this study: a valine to alanine substitution at codon 167 (UGT1A9 167Ala ) and a cysteine to glycine substitution at codon 183 (UGT1A9 183Gly ). Functional characterization of these SNPs with respect to UGT1A9 activity is described.
Materials and Methods
Chemicals and Materials. 3-Hydroxy-benzo [a] pyrene (3-OH-B[a]P) was purchased from the National Cancer Institute Chemical Carcinogen Repository (Midwest Research Institute, Kansas City, MO). 4-Aminobiphenyl (4-ABP) was purchased from Toronto Research Chemicals (Toronto, ON, Canada). Benzidine and 4-methylumbelliferone (4-MU) were purchased from SigmaAldrich (St. Louis, MO). 11-Hydroxy-dibenzo[a,l]pyrene (11-OH-DB[a,l]P) was obtained from the Penn State College of Medicine (Hershey, PA) Organic Synthesis Core. Alamethicin, UDPGA, and ␤-glucuronidase were purchased from Sigma-Aldrich, and Dulbecco's modified Eagle's medium, fetal bovine serum, and Geneticin (G418) were purchased from Invitrogen (Carlsbad, CA). The human UGT1A Western blotting kit that includes the anti-UGT1A polyclonal antibody was purchased from BD Gentest (Woburn, MA), whereas the anti-␤-actin monoclonal antibody was obtained from Sigma-Aldrich.
Study Population. For the identification of UGT1A9 polymorphisms and determination of prevalence in different racial groups, our population included 253 whites, 164 African Americans, and 59 Asians as described previously (Richie et al., 1997; Park et al., 2000; Elahi et al., 2003) . The allele and genotype frequencies for polymorphisms in the CYP1A1, CYP2E1, GSTM1, GSTT1, and GSTP1 genes in this population were similar to those observed in a pooled analysis of more than 15,000 subjects who served as controls in other case-control studies (Garte et al., 2002) . Buccal cell samples were collected from all subjects and used for the analysis of polymorphic UGT1A9 genotypes. Protocols involving the collection and analysis of buccal cell specimens were approved by the institutional review board at the H. Lee Moffitt Cancer Center and collaborating institutes and were in accordance with assurances filed with
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1. Sequence alignment of selected UGTs. The amino acid sequences of full-length UGT1A family members along with UGT2B7 were retrieved from the National Center for Biotechnology Information Protein Data Bank and aligned using the online program ClustalW2 (see Materials and Methods). Each of the UGT1A family members contains a unique exon 1 that encodes variable N-terminal amino acids, but each UGT1A shares common exons 2 to 5 coding for the same C-terminal amino acids (shown by the underline); all UGT2B enzymes are derived from unique exons. UGT2B7 is shown as a reference to compare the amino acid similarities and differences with the UGT1A enzymes. Met33, Val167, and Cys183 of UGT1A9 and these amino acids at analogous positions of other UGTs are in bold boxes to show conservation. An asterisk ‫)ء(‬ indicates an amino acid fully conserved in all UGT1As as well as UGT2B7, and a colon (:) and periods (.) indicate highly conserved and moderately conserved amino acids, respectively, in UGT enzymes. The nine cysteines that are highly conserved in the UGTs are in light boxes within the UGT sequences. The UGTs are ordered in the alignment by overall conservation of amino acids.
and approved by the U.S. Department of Health and Human Services. Informed consent was obtained from all subjects. DNA Sequencing and PCR-RFLP. DNA sequencing was performed at the Penn State College of Medicine Core Facility. For PCR-RFLP analysis, a 760-base pair fragment inclusive of the UGT1A9 exon 1 was amplified from genomic DNA for all samples by PCR following established protocols using the following primer set: UGT1A9 RFLP sense (5Ј-TTTGTGCTGGTATT TCTC-3Ј), corresponding to bases Ϫ80 to Ϫ63 relative to the UGT1A9 translation start site, and UGT1A9 RFLP antisense (5Ј-ACCGTTTTT-TCAAAAATGCC-3Ј), corresponding to bases ϩ661 to ϩ680 relative to the translation start site (GenBank accession number NM_021027). For identified polymorphisms, PCR products for all samples were then subjected to RFLP analysis with the appropriate enzyme to determine the genotype. The enzymes were HpyCH4V for codon 3, NcoI for codon 33, BsbI for codon 167, and NlaIII for codon 183.
Cloning, Site-Directed Mutagenesis, and Generation of Cell Lines. The wild-type UGT1A9 cDNA was obtained by reverse transcriptase-PCR from total RNA isolated from normal human liver using oligo(dT) as the primer. UGT1A9 cDNA was amplified by PCR using the following primers: UGT1A9 sense (5Ј-AGTTCTCTGATGGCTTGC-3Ј), corresponding to bases Ϫ9 to ϩ9 relative to the UGT1A9 translation start site, and UGT1A9 antisense (5Ј-TTTTACCTTATTTCCCACCC-3Ј) corresponding to bases ϩ9 to ϩ28 relative to the UGT1A9 translation stop site (GenBank accession number NM_021027). PCR products were confirmed by dideoxy sequencing and then cloned into the pcDNA3.1 TOPO mammalian expression plasmid (Invitrogen).
UGT1A9 variants were generated by PCR amplification of the pcDNA3.1/ V5-His-TOPO vector containing the wild-type UGT1A9 sequence with sitedirected mutagenesis primers specific for individual polymorphic site using the QuikChange kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol. The primers used to generate the UGT1A9 33Thr variant were 5Ј-GCTACTGGTAGTGCCCACGGATGGGAGCCACTGG-3Ј and 5Ј-CCAGT-GGCTCCCATCCGTGGGCACTACCAGTAGC-3Ј, corresponding to bases ϩ81 to ϩ114 relative to the UGT1A9 translation start site; the primers used to generate the UGT1A9 167Ala variant were 5Ј-CTCCCTCCCCTCCGT GGCCT-TCGCCAGGGGAATAC-3Ј and 5Ј-GTATTCCCCTGGCGAAGGCCACG-GAGGGGAGGGAG-3Ј, corresponding to bases ϩ483 to ϩ517 relative to the UGT1A9 translation start site; and the primers used to generate the UGT1A9 183Gly variant were 5Ј-GAAGAAGGTGCACAGGGCCCTGCTC-CTCTTTCCTA-3Ј and (5Ј-TAGGAAAGAGGAGCAGGGCCCTGTGCAC-CTTCTTC-3Ј, corresponding to bases ϩ532 to ϩ566 relative to the UGT1A9 translation start site (the polymorphic bases are denoted in bold for all primers). The entire coding region for each generated UGT1A9 variant was confirmed by dideoxy DNA sequencing analysis.
Stable UGT1A9-overexpressing cell lines were generated as described previously Sun et al., 2007) . In brief, the individual UGT1A9 variants were transfected into HEK293 cells (purchased from American Type Culture Collection; Manassas, VA) by electroporation. Stable transfectants that overexpressed the individual UGT1A9 variants were selected by treatment with G418 (Invitrogen).
Cellular Microsomal Preparation. Cell homogenates were prepared by resuspending pelleted cells in Tris-buffered saline (25 mM Tris base, 138 mM NaCl, and 2.7 mM KCl; pH 7.4) and subjecting them to three rounds of freeze-thaw before gentle homogenization. Microsomes were prepared from homogenates by centrifugation at 10,000g for 20 min at 4°C followed by ultracentrifugation of the supernatant at 100,000g for 1 h at 4°C to pellet the microsomal fraction. The pellet was then resuspended in Tris-buffered saline and stored in 100-l aliquots at Ϫ70°C. Total cellular microsomal protein concentrations were determined using the BCA assay from Pierce Biotechnology (Rockford, IL) after protein extraction using standard protocols.
Western Blot Analysis. SDS-polyacrylamide gel electrophoresis under reducing and nonreducing conditions was performed essentially as described previously (Chen et al., 1997; Ghosh et al., 2001 ) with the 2ϫ nonreducing buffer containing 1% SDS, 125 mM Tris-HCl, pH 6.8, 20% glycerol, and 0.5% bromphenol blue. For reducing conditions, ␤-mercaptoethanol (5% final concentration) was added to the nonreducing sample buffer. All samples were boiled for 5 min before loading. The protein ladder Precision Plus Dual Color Prestained marker (Bio-Rad Laboratories, Hercules, CA) was used to assess protein size. Levels of UGT1A9 protein in UGT1A9-overexpressing cell lines were measured by Western blot analysis using the anti-UGT1A antibody (1:5000 dilution as per the manufacturer's instructions), and housekeeping protein levels were assayed using a 1:5000 dilution of ␤-actin. Proteins were detected by chemiluminescence using the SuperSignal West Dura Extended Duration Substrate (Pierce Biotechnology, Rockford, IL). Secondary antibodies supplied with the Dura ECL kit (anti-rabbit and anti-mouse) were used at 1:3000. Relative UGT1A protein levels were quantified against a known amount of human UGT1A protein (100 ng, supplied in the Western blotting kit provided by BD Gentest) by densitometric analysis of X-ray film exposures (5 s-2-min exposures) of Western blots using a GS-800 densitometer with Quantity One software (Bio-Rad Laboratories). Quantification was done relative to the levels of ␤-actin observed in each lane. X-ray film bands were always below densitometer saturation levels as indicated by the densitometer software. Relative UGT1A protein levels are reported as the mean of three independent Western blot experiments, with Western blot analysis performed using the same UGT1A9-containing microsomes used for activity assays.
Glucuronidation Assays. The rate of glucuronidation by UGT1A9-overexpressing cell microsomes was determined essentially as described previously (Fang et al., 2002; Wiener et al., 2004; Al-Zoughool and Talaska, 2005; Dellinger et al., 2006 Dellinger et al., , 2007 . For glucuronidation rate determinations, substrate concentrations, microsomal protein levels, and incubation times for individual assays were chosen to maximize levels of detection within a linear range of uptake and were similar to established protocols (Fang et al., 2002; Wiener et al., 2004; Dellinger et al., 2007; Sun et al., 2007) . For O-glucuronidated substrates, kinetic analysis against 3-OH-B[a]P was performed using UGT1A9-overexpressing cell microsomes (1 g of protein) preincubated with alamethicin (50 g/mg protein) for 10 min on ice. The final incubation reaction was carried out (100 l final volume) in 50 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 4 mM UDPGA, and 0.01 to 0.6 M 3-OH-B[a]P at 37°C for 15 min. For kinetic analysis of 11-OH-DB[a,l]P, conditions were the same except that 2 g of microsomal protein was used, and the reaction was carried out for 30 min with a substrate concentration range of 0.08 to 5 M. For kinetic analysis of 4-MU, 5 g of microsomal protein was used with a substrate concentration range of 100 to 1200 M for UGT1A9 33Thr and 1 to 64 M for wild-type UGT1A9, UGT1A9 167Ala , and UGT1A9 183Gly . For N-glucuronidated substrates, kinetic analysis of 4-ABP was performed using microsomes (40 g of protein) as described above except that the 4-ABP concentration range was 31 to 4000 M with an incubation time of 120 min. Reactions with benzidine were performed under the same conditions as those for 4-ABP except that 100 g of microsomal protein was used with a substrate concentration range of 250 to 8000 M. For all calculations involving these UGT1A9-overexpressing cell microsomes, the maximum rate (V max ) was normalized to UGT levels in the respective cell line based on Western blot analysis of protein expression for that line. The chosen substrate concentration ranges encompassed the apparent Michaelis constant (K m ) for all conditions tested. Reactions were terminated by the addition of an equal volume of 100% acetonitrile on ice. The reactions were centrifuged at 16,000g for 10 min at 4°C, and the supernatant (200 l) was analyzed by an ultra-performance liquid chromatography system (Acquity; Waters, Milford, MA), equipped with a UV detector operated at 310 nm (3-OH-B[a]P), 305 nm (11-OH-DB[a,l]P), 316 nm (4-MU), or 280 nm (4-ABP and benzidine), using an ultra-performance liquid chromatography BEH C18 1.7-m 2.1 ϫ 100 mm column (Acquity; Waters). For both 3-OH-B[a]P and 11-OH-DB[a,l]P, supernatants were concentrated in a SpeedVac and subsequently resuspended in 20 l of a 50:50 water-acetonitrile solution to allow for glucuronide detection using low concentration ranges for these substrates. The following gradient conditions were used for 4-ABP: 80% buffer A (5 mM ammonium acetate, pH 5.0) for 1 min, followed by a linear gradient up to 70% buffer B (100% acetonitrile) over 2 min at a flow rate of 0.3 ml/min. For benzidine, the same buffers were used, except the percentages were adjusted to 95% buffer A with a linear gradient up to 75% of buffer B. For 4-MU, the same buffers were used, except that the percentages were adjusted to 98% buffer A with a linear gradient up to 70% of buffer B and a flow rate of 0.5 ml/min. For 3-OH-B[a]P and 11-OH-DB[a,l]P, buffer A contained 5 mM ammonium acetate (pH 5.0) plus 10% acetonitrile. 3-OH-B[a]P conditions were 89% buffer A with a linear gradient up to 67% buffer B at a flow rate of 0.3 ml/min. 11-OH-DB[a,l]P conditions were 78% buffer A with a linear gradient up to 75% buffer B at a flow rate of 0.5 ml/min. Untransfected HEK293 cells were used as a negative control, and putative glucuronide peaks were confirmed first dmd.aspetjournals.org using ␤-glucuronidase and then liquid chromatography-mass spectrometry as described previously (Dellinger et al., 2006; Sun et al., 2007) . Experiments were always performed in triplicate as independent assays. Data Analysis. GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA) was used to calculate kinetic values. Kinetic constants for glucuronidation of all the substrates were calculated using the Michaelis-Menten equation (eq. 1): , the data points were fitted to the substrate inhibition model illustrated in Scheme 1 with eq. 2:
where K i is the substrate inhibition constant. For the reaction of 3-OH-B[a]P with UGT1A9 33Thr and UGT1A9 183Gly , the data points were fitted to the substrate activation model in Scheme 2 with eq. 3:
where K S is the substrate dissociation constant, ␣K S is the dissociation constant of the second substrate molecule, and ␤k cat is the rate constant for the product formation from the ESS complex. Student's t test (two-sided) was used for comparing rates and kinetic values of glucuronide formation for the UGT1A9 variants relative to wild-type UGT1A9 against the different substrates examined in this study. The sequence alignment in Fig. 1 was generated by retrieving amino acid sequences for the selected UGTs from the National Center for Biotechnology Information database and inputting them in FASTA format in the online program ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/index.html). Additional annotation to indicate residues or motifs of importance was done by the authors. The structures in Fig. 4 were generated by the program ISIS/Draw.
Results

Identification of Novel Missense Polymorphisms in UGT1A9.
Informative sequencing information for all UGT1A9 exon 1 sequences was obtained for 90 healthy subjects (43 African Americans and 47 whites). In addition to a previously identified MetϾThr SNP at codon 33 of the UGT1A9 gene (Villeneuve et al., 2003) , two novel missense polymorphisms were identified (Table 1) : a TϾC at base 500 relative to the UGT1A9 translation start site resulting in a ValϾAla change at UGT1A9 codon 167 and a TϾG at base 547 relative to the UGT1A9 translation start site resulting in a CysϾGly change at UGT1A9 codon 183. Neither of these SNPs was described in public SNP databases including the International HapMap Project. The prevalence of each missense polymorphism was determined by PCR-RFLP analysis of buccal cell DNA from an additional 206 whites, 121 African Americans, and 59 Asians. The prevalences of the UGT1A9 167Ala and UGT1A9 183Gly variant alleles were both 0.01 in whites and 0.003 and 0.004, respectively, in African Americans (Table 1) . Neither of these missense UGT1A9 variant alleles was found in any of the Asian subjects examined. The prevalence of the UGT1A9 33Thr variant was also assessed in our population and was found to be 0.01 in both whites and African Americans and absent from the Asian population. All of the subjects for which a polymorphism was identified were heterozygous for the polymorphic allele. In addition, a previously reported UGT1A9 SNP at codon 3 (Villeneuve et al., 2003) was not detected in our populations. None of the variants were linked to each other in any of the subjects examined.
UGT1A9 Variant Activity Analysis. HEK293 cells were stably transfected to overexpress wild-type UGT1A9 (UGT1A9 33Met/167Val/183Cys ). To assess whether the missense SNPs in UGT1A9 altered UGT1A9 functional activity, the polymorphic UGT1A9 variants (UGT1A9 33Thr , UGT1A9 167Ala , and UGT1A9 183Gly ) were generated by site-directed mutagenesis and individually overexpressed in HEK293 cells because this cell line lacks endogenous UGT expression. Semiquantitative Western blot analysis was used to determine the expression levels of the individual enzymes (Fig. 2) . All four cell lines exhibited high levels of UGT1A9 expression. In addition to the band corresponding to the expected UGT1A9 protein at ϳ50 kDa, a second band of ϳ100 kDa was observed for wild-type UGT1A9 as well as for the UGT1A9 33Thr and UGT1A9 167Ala variants in native polyacrylamide gels ( Fig. 2A) . This additional band was not observed for the UGT1A9 183Gly variant. When UGT1A9-overexpressing HEK293 cell protein was incubated under reducing conditions, the 100-kDa band was no longer detected for any of the UGT1A9 isoforms ( Fig.  2A) . The protein levels of all four UGT1A9 isoforms were determined relative to ␤-actin (an internal reference for expression) by densitometry under reducing conditions (Fig. 2B ) and used for normalization of microsomal protein for glucuronidation assays of known substrates of UGT1A9 (described below).
UGT1A9 was shown previously to exhibit the highest Oglucuronidating activity of any hepatic UGT against several monohydroxylated B[a]P metabolites including 3-OH-B[a]P (Dellinger et al., 2006) . 4-MU is O-glucuronidated by many UGT enzymes including UGT1A9 (Mano et al., 2004) . In addition to these documented Oglucuronidated substrates of UGT1A9, we tested the O-glucuronidation activity of UGT1A9 against 11-OH-DB[a,l]P, a metabolite of DB[a,l]P, which is found in cigarette smoke and is also released in the environment as a result of incomplete combustion of coal and has been proposed as the most potent procarcinogen of all polycyclic aromatic hydrocarbons (Ralston et al., 1995) . Although UGT1A9 N-glucuronidating activity is limited, only two UGTs, 1A4 and 1A9, were shown to N-glucuronidate 4-ABP (Al-Zoughool and Talaska, SCHEME 1. Substrate inhibition. , and UGTs1A4 and 1A9 had the highest levels of Nglucuronidating activity against benzidine (Ciotti et al., 1999) .
To determine whether the polymorphic variants of UGT1A9 produced functional alterations in UGT1A9 O-and/or N-glucuronidation activity, steady-state kinetic analysis was performed using wild-type and variant UGT1A9-overexpressing HEK293 microsomes in glucuronidation assays with benzidine, 4-ABP, 4-MU, 11-OH-DB[a,l]P, or 3-OH-B[a]P as substrates. The initial rate versus substrate concentration plots are shown in Fig. 3 . To evaluate whether the initial rate kinetics were consistent with simple Michaelis-Menten kinetics, the data were transformed to the Eadie-Hofstee plots (Supplemental Fig.  1 ). In most cases, the linear Eadie-Hofstee plots indicated that the reactions exhibited Michaelis-Menten kinetics and were fit to eq. 1.
The N-glucuronidation of benzidine by the three UGT1A9 variants was not significantly different from that observed for wild-type UGT1A9 ( Fig. 3 ; Table 2 ). Glucuronidation of benzidine by human liver microsomes resulted in a much higher glucuronide peak compared with that for UGT1A9 alone (results not shown), demonstrating that other UGTs (probably UGT1A4) contribute to the Nglucuronidation of this compound. N-Glucuronidation of 4-ABP by wild-type UGT1A9 microsomes was approximately 30-fold higher than that of benzidine ( Fig. 3; Table 2 ). However, a significantly higher K m and lower V max was observed for the UGT1A9 33Thr variant for 4-ABP, which resulted in significantly decreased overall glucuronidation (V max /K m ) compared with that for wild-type UGT1A9. The UGT1A9 167Ala variant exhibited a slightly lower K m with no change in V max or overall glucuronidation efficiency. The UGT1A9 183Gly variant exhibited a significantly increased K m and 2-fold higher V max compared with those for wild-type UGT1A9, leading to an overall increased glucuronidation efficiency of this mutant versus wild type.
The O-glucuronide substrates were glucuronidated with much higher efficiency by UGT1A9 variants than the two N-glucuronidated substrates examined in this study. Whereas the UGT1A9 33Thr mutant exhibited large significant increases in K m and V max and a 25-fold decrease in V max /K m compared with those for wild-type UGT1A9 against 4-MU ( Fig. 3; Table 2 ), slight increases in V max and no significant difference in K m were observed for the UGT1A9 167Ala and UGT1A9 183Gly variants ( Fig. 3 ; Table 2 ). Glucuronidation of 11-OH-DB[a,l]P was unchanged for the UGT1A9 33Thr and UGT1A9 167Ala variants, compared with that for wild-type UGT1A9. The glucuronidation of 11-OH-DB[a,l]P by UGT1A9 183Gly exhibited substrate inhibition as detected by the reduction in v at high substrate concentrations (Fig. 3) and the decrease in v at low v/ [S] values in the Eadie-Hofstee transformed data (Supplemental Fig. 1) . Thus, these data were fitted to the substrate inhibition kinetic scheme illustrated in Scheme 1 with eq. 2. The UGT1A9 183Gly variant demonstrated a 3-fold higher K m , 2-fold higher V max , and a nearly 2-fold decrease in overall enzyme efficiency compared with those for the wild type ( Table 2 ). The substrate inhibition constant (K i ) was 6.6 M, approximately 8-fold higher than the K m value.
For 3-OH-B[a]P, the wild-type UGT1A9 and the UGT1A9 167Ala variants exhibited substrate inhibition kinetics as evidenced by the decreased initial rates at high substrate concentrations (Fig. 3) and curvilinear Eadie-Hofstee plots (Supplemental Fig. 1) . Therefore, the data for both cases were fitted to the substrate inhibition equation (eq. 2). The K m value for UGT1A9 167Ala was almost 2-fold higher than that for the wild type. V max values for wild-type UGT1A9 and UGT1A9 167Ala were virtually the same. The K i values were identical (0.42 M) for both UGT1A9 167Ala and wild-type UGT1A9 (Table 2 ). The UGT1A9 33Thr and UGT1A9 183Gly variants exhibited nonMichaelis-Menten kinetics (Fig. 3) , which was evident after transformation of the data using the Eadie-Hofstee transformation (Supplemental Fig. 1 ). Because the downward curves of Eadie-Hofstee plots at low v/[S] values suggested substrate inhibition, the upward curve at low v/[S] values for UGT1A9 33Thr and UGT1A9 183Gly against 3-OH-B[a]P suggested substrate activation. The simplest kinetic scheme that could account for the substrate activation is illustrated in Scheme 2. The rate equation for this scheme is presented in eq. 3, where the dissociation constant for the second substrate molecule is ␣K S and the ESS complex forms product at the rate ␤k cat . Overall, the kinetic parameters of these fits had large SDs from the mean; however, this is expected as eq. 3 has four variables with a limited amount of data points to fit to a curve. The mean K S values for UGT1A9 33Thr and UGT1A9 183Gly (both 0.02 M) were decreased 6-fold from those for the wild type; however, the large SD values made the difference between UGT1A9 33Thr and the wild type not statistically different. The large values for ␣ (␣ Ͼ 50) in both cases indicate that the second substrate molecule binds to the complex with less affinity than the first. The V max values for UGT1A9 33Thr and UGT1A9 183Gly were FIG. 2. Analysis of UGT1A9 monomer and homodimer expression. Representative Western blot analysis of the individual UGT1A9-overexpressing cell lines from microsomal protein lysates used in this study. Protein lysate (20 g) of the indicated UGT1A9 variant overexpressing or parental HEK293 cell line was loaded in each lane and screened using a UGT1A-specific antibody (BD Gentest). A, Western blot analysis of UGT1A9 using SDS-polyacrylamide gel electrophoresis. The first five lanes were run under nonreducing conditions, whereas the last four lanes were run under reducing conditions by the addition of ␤-mercaptoethanol as described under Materials and Methods. B, Western blot analysis of ␤-actin. The same blot was stripped and reprobed for ␤-actin. The relative expression of each UGT1A9 variant was determined by the average of three independent Western blot experiments normalized to ␤-actin. Wild-type UGT1A9 refers to UGT1A9 33Met/167Val/183Cys
. dmd.aspetjournals.org significantly lower than those observed for the wild type. However, the large ␤ value (␤ Ͼ 5 in both cases) indicates that the initial rate of reaction at saturating substrate concentrations would be the same as that for the wild type. The overall enzyme efficiency of each of the three variants against 3-OH-B[a]P was unchanged compared with that for the wild type.
Discussion
UGT1A9 has been shown to play an important role in the detoxification of several carcinogens and clearance of anticancer agents and other drugs. In this report, we describe the presence of several lowprevalence SNPs that result in missense changes in the UGT1A9 amino acid sequence.
The previously described SNP resulting in the UGT1A9 33Thr variant (Villeneuve et al., 2003) , which was also identified in both whites and African Americans in the present study, exhibited changes in O-glucuronidation activity against 4-MU and 3-OH-BaP but not 11-OH-DB[a,l]P. Likewise, although a large decrease in activity was observed for this variant against 4-ABP, no difference in activity was observed against benzidine. These results agree with previous studies demonstrating that the UGT1A9 33Thr variant exhibited efficient glucuronidation activity against flavopiridol but exhibited a 26-fold decrease in activity against SN-38 (Villeneuve et al., 2003) and significant decreases in glucuronidation activity against mycophenolic acid (Bernard and Guillemette, 2004) and the 4-hydroxylated metabolites of the hormones estradiol and estrone (Thibaudeau et al., 2006) . Together, these studies suggest that the glucuronidation efficiency of the UGT1A9 33Thr variant seems to be highly substrate-dependent. It is interesting to note that UGT1A4, which participates primarily in N-glucuronidation, harbors a threonine at the position analogous to Met33 of UGT1A9 (Fig. 1) . Because substrate-dependent glucuronidation efficiency was observed for both O-and N-glucuronidated substrates in this study, it seems that Met33 is probably not a discriminating residue for O-versus N-glucuronidation.
Two novel missense SNPs at codons 167 and 183 of the UGT1A9 gene were identified in this study. The UGT1A9 167Ala variant exhibited minimal differences in overall glucuronidation activity compared with wild-type UGT1A9 against all substrates tested in this study. This result is consistent with the fact that this polymorphism is relatively conservative, resulting in no changes in charge or polarity at UGT1A9 residue 167. Therefore, such an amino acid change would not be expected to drastically affect enzymatic activity. Cys183 is a highly conserved amino acid within the UGT1A family because it is present in all UGT1A enzymes except UGT1A6 (Fig. 1) . Previous studies using two-hybrid screening (Ghosh et al., 2001) or fluorescence resonance energy transfer analysis (Operaña and Tukey, 2007) demonstrated that human UGT1A enzymes may homodimerize. The present study is the first report to identify a cysteine residue that is required for homodimerization of a human UGT. Unlike the strong homodimerization observed for wild-type UGT1A9 or the UGT1A9 33Thr and UGT1A9 167Ala variants, the UGT1A9 183Gly variant specifically exhibited no dimerization potential in the present study, suggesting that the wild-type cysteine at codon 183 is central to UGT1A9 homodimerization. There are 13 cysteine residues in UGT1A9, with 9 conserved among the majority of other human UGT1A enzymes (Fig. 1) as well as UGT family members from other mammals (Ghosh et al., 2005) . Mutations of each of the 11 cysteine residues in human UGT1A1 were shown to differentially alter O-glucuronidation activity against bilirubin, but this report did not address dimerization directly (Ghosh et al., 2005) . Similar to the current study, mutation of the cysteine at amino acid residue 186 of the UGT1A1 protein (the analogous cysteine to UGT1A9 codon 183) demonstrated a 2-fold reduction in O-glucuronidation activity against bilirubin (Ghosh et al., 2005) . Western blot analysis showed that neither the wild-type UGT1A1 nor the Cys186 variant was found to homodimerize, suggesting that the reduced activity of the variant was not attributed to the lack of dimerization through disulfide bonds but rather the absence of the free thiol groups needed for glucuronidation (Ghosh et al., 2005) . In the present study, the glucuronidation efficiency of the UGT1A9 183Gly mutant was slightly altered, with significantly altered glucuronidation activities against 4-ABP and 11-OH-DB[a,l]P. The glucuronidation efficiency of benzidine, 4-MU, and 3-OH-B[a]P remained relatively unchanged. The abundance of UGT1A9 present in the HEK293 cells may also favor homodimerization of the enzyme, although if this is the case, only 50% of UGT1A9 is dimerized as indicated by the Western blot data (Fig. 2) . Thus, it seems that although a change of the codon 183 cysteine may slightly alter UGT1A9 activity against some substrates, the homodimerization of UGT1A9 is not required for efficient glucuronidation of the substrates we tested.
Little is known about how UGTs select their substrates; however, two recent studies identified amino acids that may facilitate unique substrate recognition. In one study, two residues of UGT1A9, Arg42 and Asn152, were identified as contributing to substrate specificity of the enzyme (Fujiwara et al., 2009 ). The importance of Arg42 and Asn152 was determined using mutational analysis of these amino acids analogous to those found in UGT1A8. In another study, a very low-prevalence polymorphism in the Japanese population, resulting in an aspartic acid to asparagine amino acid change at codon 256 in UGT1A9, differentially affected UGT1A9 glucuronidation of substrates such as propofol and mycophenolic acid (Takahashi et al., 2008) . Consequently, these discriminating residues may be a part of the UGT1A9 substrate binding pocket, and major amino acid changes would affect the glucuronidation ability of the enzyme. In the current study, the UGT1A9 33Thr mutant exhibited the most dramatic substrate-specific decreases in glucuronidation efficiency. Therefore, it may potentially be part of the substrate binding site and serve as a discriminating residue for substrate selection.
The substrates we tested in the current study are depicted in Fig. 4 so that the ϪNH 2 or ϪOH acceptor group of each substrate is oriented in the same way. In examining the substrates in this manner, it is possible to visualize how the UGT1A9 substrate-binding pocket may accommodate the different structures. Further work with these substrates is needed to determine the structure-function relationship that is taking place. The glucuronidation of substrates by the UGT family of enzymes is quite variable and is complicated further with the effects of amino acid changes in UGT variants, depending on the severity of change and function of the amino acid. As is clearly the case for 3-OH-B[a]P, the reaction did not follow simple Michaelis-Menten kinetics in the present study. The wild-type UGT1A9 and UGT1A9 167Ala followed substrate ). ** P Ͻ 0.01. *** P Ͻ 0.001. against 11-OH-DB[a,l]P also followed substrate inhibition kinetics. The kinetic analyses for UGT1A9 33Thr and UGT1A9 183Gly against 3-OH-B[a]P were best fit to Scheme 2, although this does not prove that the reaction occurs via Scheme 2. Complex reaction schemes have been observed previously with UGTs, as Houston and Kenworthy (2000) , Galetin et al. (2002) , and Uchaipichat et al. (2004 Uchaipichat et al. ( , 2008 have observed kinetics consistent with multiple substrate binding and acceptor sites.
In summary, in addition to a previously identified SNP at UGT1A9 codon 33 (Villeneuve et al., 2003) , two novel low-prevalence missense SNPs were identified in the UGT1A9 gene in this study, both exhibiting relatively modest substrate-specific changes in glucuronidation activity compared with wild-type UGT19. This is the first report to identify a cysteine that is required for human UGT homodimerization, and this result could yield valuable insight into the dynamics of the glucuronidation reaction. Although the lack of homodimerization observed for the UGT1A9 183Gly variant did not greatly affect UGT1A9 glucuronidation activity against the substrates tested in the present study, a larger evaluation of other substrates may be necessary to examine the overall role of homodimerization on UGT1A9 glucuronidation activities. 
